Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Original languageEnglish (US)
Pages (from-to)416-423
Number of pages8
JournalOncology (Williston Park, N.Y.)
Volume29
Issue number6
Publication statusPublished - Jun 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this